50 completed, 17 terminated, 12 recruiting, 9 withdrawn. 104 Phase 1, 44 Phase 2.
Follow Stem Cell Transplantation: new trials by email Literature Review of Stem Cell Transplantation trials Research Report on Stem Cell Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-10-30 |
| A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia Anti-Thymocyte Globulin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2024-11-15 | 2026-01-05 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-06-05 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs. Hematopoietic cell transplantation, Total Lymphoid irradiation - Immune Tolerance | Phase 1 | Recruiting | Stephan Busque | 25 | 2024-02-02 | 2026-07-01 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine - Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2023-03-01 | 2023-04-27 | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 7 | 2022-07-19 | 2026-07-06 |
| TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2022-07-13 | 2026-07-30 |
| Personalized Autologous Transplant for Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Melphalan, Questionnaire Administration - Multiple Myeloma | Phase 1 | Recruiting | Emory University | 90 | 2021-05-20 | 2026-06-15 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
Showing 20 of 104. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Myelodysplastic Syndromes (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Lymphoma (13) · Leukemia (12) · Lymphoma, Non-Hodgkin (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Multiple Myeloma (9) · Hodgkin Disease (5) · Lymphoma, Large B-Cell, Diffuse (5) · Neuroblastoma (5) · Anemia, Sickle Cell (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma, Follicular (4) · Neoplasms, Plasma Cell (4)
M.D. Anderson Cancer Center (16) · City of Hope Medical Center (13) · Fred Hutchinson Cancer Center (7) · Royan Institute (7) · Stem Cells Arabia (5) · Washington University School of Medicine (5) · Masonic Cancer Center, University of Minnesota (4) · Baylor College of Medicine (3) · Ohio State University Comprehensive Cancer Center (3) · Children's Oncology Group (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · OHSU Knight Cancer Institute (2) · Richard Burt, MD (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · St. Jude Children's Research Hospital (2)
United States (81) · Iran (7) · Jordan (4) · Vietnam (2) · Australia (1) · Brazil (1) · Canada (1) · Egypt (1) · New Zealand (1) · Saudi Arabia (1) · Turkey (Türkiye) (1)
Hamid Gourabi, PhD (7) · Nasser Aghdami, MD,PhD (6) · Andrew Artz, MD (2) · Jeffrey Y Wong (2) · Leila Arab, MD (2) · Margaret MacMillan, MD (2) · Partow Kebriaei, MD (2) · Phuong Vo (2) · Richard Burt, MD (2) · Ryotaro Nakamura (2) · Yago Nieto, MD, PHD (2) · Adeeb AlZoubi, PhD (1) · Alain Mina, M.D. (1) · Ali Reza Zali, MD (1) · AliReza Zaali, MD (1)
PMID 27482888, PMID 20919852, PMID 21868572, PMID 21991976, PMID 22405058, PMID 23364976, PMID 23912587, PMID 24508444, PMID 25593079, PMID 25824692, PMID 26058927, PMID 26123356, PMID 27118452, PMID 27293053, PMID 28292947, PMID 28296863, PMID 28396162, PMID 28403842, PMID 29021519, PMID 30124008, PMID 32840230, PMID 33407794, PMID 33951890, PMID 34028986, PMID 34312462, PMID 34432869, PMID 34515338, PMID 35354808, PMID 36402456, PMID 39576962, PMID 40331908, PMID 41488889, PMID 42537695
P30CA033572 (10), P30CA016672 (3), P01HL075462 (2), U10CA098543 (2), U10CA180886 (2), K12CA167540 (1), P01CA049639 (1), P01CA078902 (1), P01CA081403 (1), P01HL122173 (1), P30CA012197 (1), P30CA015704 (1), P30CA138292 (1), P50CA107399 (1), R01AI041721 (1)